Preferential inhibition of phosphodiesterase 4 (PDE4) B in patients with pulmonary fibrosis could provide anti-inflammatory and antifibrotic effects with improved safety compared with pan-PDE4 inhibitors.https://bit.ly/3UE0CdU. Here, PDE4A is linked to pulmonary fibrosis.